Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Public ClinicalTrials.gov record NCT04585815. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination. Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated. Sub-study B is complete. All participants have discontinued treatment and any additional follow up required by protocol.
Study identification
- NCT ID
- NCT04585815
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Interventions
- Sasanlimab Prefilled syringe Drug
- Encorafenib Drug
- Binimetinib Drug
- Sasanlimab Drug
- Axitinib Drug
- SEA-TGT Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 10, 2020 (Actual)
- Primary completion
- May 17, 2023 (Actual)
- Completion
- Oct 29, 2024 (Actual)
- Last update posted
- Jan 9, 2026
2020 – 2024
United States locations
- U.S. sites
- 43
- U.S. states
- 5
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Investigational Drug Services (IDS) | Duarte | California | 91010 | — |
| City of Hope | Duarte | California | 91010 | — |
| UCSD Medical Center - Encinitas | Encinitas | California | 92024 | — |
| California Cancer Associates for Research and Excellence, Inc (cCARE) | Fresno | California | 93720 | — |
| The Oncology Institute of Hope and Innovation | Glendale | California | 91204 | — |
| Koman Family Outpatient Pavilion | La Jolla | California | 92037 | — |
| Sulpizio Cardiovascular Center at UC San Diego Health | La Jolla | California | 92037 | — |
| UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) | La Jolla | California | 92037 | — |
| UC San Diego Moores Cancer Center - Investigational Drug Services | La Jolla | California | 92037 | — |
| UCSD Perlman Medical Offices | La Jolla | California | 92037 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| The Oncology Institute of Hope and Innovation | Long Beach | California | 90805 | — |
| The Oncology Institute of Hope and Innovation | Los Angeles | California | 90015 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| UC San Diego Medical Center - Hillcrest | San Diego | California | 92103 | — |
| The Oncology Institute of Hope and Innovation | Santa Ana | California | 92705 | — |
| UCSD Medical Center - Vista | Vista | California | 92081 | — |
| The Oncology Institute of Hope and Innovation | Whittier | California | 90602 | — |
| AdventHealth Celebration Infusion Center | Celebration | Florida | 34747 | — |
| AdventHealth Medical Group Oncology Research at Celebration | Celebration | Florida | 34747 | — |
| Advent Health Orlando - Investigational Drug Services | Orlando | Florida | 32804 | — |
| AdventHealth Orlando Infusion Center | Orlando | Florida | 32804 | — |
| AdventHealth Orlando | Orlando | Florida | 32804 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Henry Ford Medical Center - Fairlane | Dearborn | Michigan | 48126 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Henry Ford Medical Center - Columbus | Novi | Michigan | 48377 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Mount Sinai Hospital Pharmacy | New York | New York | 10029 | — |
| Tennessee Oncology PLLC | Dickson | Tennessee | 37055 | — |
| Tennessee Oncology PLLC | Franklin | Tennessee | 37067 | — |
| Tennessee Oncology PLLC | Gallatin | Tennessee | 37066 | — |
| Tennessee Oncology PLLC | Hendersonville | Tennessee | 37075 | — |
| Tennessee Oncology PLLC | Hermitage | Tennessee | 37076 | — |
| Tennessee Oncology PLLC | Lebanon | Tennessee | 37090 | — |
| Tennessee Oncology PLLC | Murfreesboro | Tennessee | 37129 | — |
| Sarah Cannon Research Institute - Pharmacy | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37205 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37207 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37211 | — |
| Tennessee Oncology PLLC | Shelbyville | Tennessee | 37160 | — |
| Tennessee Oncology PLLC | Smyrna | Tennessee | 37167 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04585815, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 9, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04585815 live on ClinicalTrials.gov.